Antitumor Effect of Triptolide in T-Cell Lymphoblastic Lymphoma by Inhibiting Cell Viability, Invasion, and Epithelial–Mesenchymal Transition via Regulating the PI3K/AKT/mTOR Pathway [Retraction]

IF 2.7 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

OncoTargets and therapy Pub Date : 2024-04-05 DOI:10.2147/ott.s472070

Yan Huang, Sun Wu, Yuan Zhang, Lihua Wang, Yan Guo

引用次数: 0

Abstract

Retraction for the article Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial–mesenchymal transition via regulating the PI3K/AKT/mTOR pathway

查看原文本刊更多论文

通过调控 PI3K/AKT/mTOR 通路抑制细胞活力、侵袭和上皮-间质转化，雷公藤内酯在 T 细胞淋巴细胞淋巴瘤中的抗肿瘤作用 [撤回］

三苯氧胺通过调节PI3K/AKT/mTOR通路抑制细胞活力、侵袭和上皮–间质转化，从而在T细胞淋巴细胞淋巴瘤中发挥抗肿瘤作用》一文的撤回声明

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY

CiteScore

9.70

自引率

0.00%

发文量

221

审稿时长

1 months

期刊介绍： OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.